Potassium%2525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCL) is an electrolyte replacement used to treat or prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. ## Adult Dosing * **Oral:** * **Prevention:** 20 mEq (10 mmol) daily. * **Treatment:** 40-100 mEq (20-50 mmol) daily, divided into 2-5 doses. * Maximum recommended daily dose: 200 mEq (100 mmol). * **Intravenous (IV):** * **Caution:** IV potassium administration requires careful monitoring due to the risk of cardiotoxicity. Dosing depends on severity of hypokalemia and patient status. * **General Replacement:** 10-20 mEq (5-10 mmol) added to a large volume IV fluid (e.g., 1 L) infused over several hours. * **Severe Hypokalemia/Symptomatic:** Doses up to 40 mEq (20 mmol) per hour may be administered in critical care settings with continuous cardiac monitoring. * Maximum concentration: Typically 40 mEq (20 mmol) per liter for peripheral IV infusion; higher concentrations may be used centrally under strict monitoring. * Maximum rate: Typically 10-20 mEq (5-10 mmol) per hour via peripheral IV; rates up to 40 mEq (20 mmol) per hour may be used centrally with cardiac monitoring. Higher rates should only be used in emergencies with continuous ECG monitoring. ## Pediatric Dosing * **Oral:** * **Maintenance:** 1-2 mEq/kg/day (0.5-1 mmol/kg/day), divided into 1-2 doses. Maximum 100 mEq (50 mmol) per day. * **Intravenous (IV):** * **General:** 0.5-1 mEq/kg/dose (0.25-0.5 mmol/kg/dose) added to IV fluids, not to exceed 10-20 mEq (5-10 mmol) per dose. * **Maximum Rate:** Typically 0.3-0.5 mEq/kg/hour (0.15-0.25 mmol/kg/hour), not to exceed 10-20 mEq (5-10 mmol) per hour. Higher rates require continuous cardiac monitoring. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Potassium chloride is generally contraindicated in severe renal impairment. Dose reductions are necessary in moderate renal impairment. Monitor potassium levels closely. ## Contraindications * Hyperkalemia. * Conditions that predispose to hyperkalemia (e.g., anuria, severe renal failure, adrenal insufficiency, untreated Addison's disease, rapid tissue breakdown). * Certain cardiac conditions where hyperkalemia can be fatal (e.g., complete heart block). * Certain gastrointestinal conditions (e.g., esophageal obstruction, delayed gastric emptying, active peptic ulcer disease) for enteric-coated oral formulations due to risk of perforation. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain. * **Serious:** * **Hyperkalemia:** Manifests as muscle weakness, fatigue, paresthesias, arrhythmias, cardiac arrest. * **Gastrointestinal:** GI bleeding, ulceration, perforation (especially with oral solid dosage forms). * **Extravasation:** (IV) Tissue necrosis, phlebitis. ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia. * **ACE inhibitors and ARBs:** Increased risk of hyperkalemia. * **NSAIDs:** May decrease potassium excretion, increasing risk of hyperkalemia. * **Digoxin:** Hyperkalemia can increase digoxin toxicity; hypokalemia can potentiate digoxin toxicity. ## Monitoring * **Serum potassium levels:** Frequently, especially during IV administration, initiation of therapy, and dose changes. * **Renal function (BUN, creatinine):** Regularly. * **ECG:** For signs of hyperkalemia (peaked T waves, flattened P waves, prolonged PR interval, QRS widening) during rapid IV infusion or in patients with renal impairment. * **Signs and symptoms of hypokalemia and hyperkalemia.** ## Clinical Pearls * Oral potassium chloride should be taken with meals or fluids to minimize gastrointestinal irritation. * Never administer IV potassium chloride undiluted as an IV push. * Rapid IV administration of potassium is dangerous and can be fatal. Always dilute and infuse slowly, with appropriate monitoring. * The risk of hyperkalemia is significantly increased in patients with impaired renal function. *** *This information is intended for clinical professionals. It is essential to consult current, official prescribing information and institutional protocols for complete and up-to-date guidance before making any clinical decisions.*